Our Technology

IVX037

IVX037 is a self-amplifying non-enveloped, single-positive-stranded RNA virus. It has been bioselected, targeting a novel receptor highly expressed in colorectal, gastric, ovarian, liver and other cancer types. IVX037 entered the clinic in 2023.

IVX055

IVX055 is a self-amplifying non-enveloped, single-positive-stranded RNA virus. It has been bioselected, targeting a novel receptor highly expressed in non-small cell lung and other cancer types. IVX055 is planned to enter the clinic in 2025.

Our Technology

Differentiated Oncolytic RNA Immunotherapy Pipeline

Pipeline
Clinical Development

Pre-clinical / discovery

The company has a well resourced team at its Newcastle R&D facility working on multiple projects including:

  • Assessment of IVX037 in additional cancer types and in combination with other therapies such as CAR-T cell.
  • Preparation of IVX055 pre-clinical and CMC data package to enable first in patient study planned to commence in 2025
  • Alternative delivery modalities
  • Expanding to other cancer indications
In the News

View our recent news stories

Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.

View All Stories